These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29946862)

  • 21. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.
    Rakovitch E; Nofech-Mozes S; Hanna W; Baehner FL; Saskin R; Butler SM; Tuck A; Sengupta S; Elavathil L; Jani PA; Bonin M; Chang MC; Robertson SJ; Slodkowska E; Fong C; Anderson JM; Jamshidian F; Miller DP; Cherbavaz DB; Shak S; Paszat L
    Breast Cancer Res Treat; 2015 Jul; 152(2):389-98. PubMed ID: 26119102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does Progesterone Receptor Matter in the Risk of Recurrence for Patients With Ductal Carcinoma in Situ?
    Chaudhary LN; Jawa Z; Hanif A; Szabo A; Kamaraju S; Cheng YC; Chitambar CR
    WMJ; 2018 Jun; 117(2):62-67. PubMed ID: 30048574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contralateral breast cancer risk and endocrine therapy use in patients with ductal carcinoma in situ treated with unilateral mastectomy in the modern era.
    ElSherif AS; Tu C; Valente SA
    Am J Surg; 2021 Mar; 221(3):521-524. PubMed ID: 33189311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.
    Schmitz RSJM; van den Belt-Dusebout AW; Clements K; Ren Y; Cresta C; Timbres J; Liu YH; Byng D; Lynch T; Menegaz BA; Collyar D; Hyslop T; Thomas S; Love JK; Schaapveld M; Bhattacharjee P; Ryser MD; Sawyer E; Hwang ES; Thompson A; Wesseling J; Lips EH; Schmidt MK;
    BMJ; 2023 Oct; 383():e076022. PubMed ID: 37903527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
    Fisher B; Bryant J; Dignam JJ; Wickerham DL; Mamounas EP; Fisher ER; Margolese RG; Nesbitt L; Paik S; Pisansky TM; Wolmark N;
    J Clin Oncol; 2002 Oct; 20(20):4141-9. PubMed ID: 12377957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.
    Cronin PA; Olcese C; Patil S; Morrow M; Van Zee KJ
    Ann Surg Oncol; 2016 Sep; 23(9):2816-24. PubMed ID: 27198513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma
    Thorat MA; Levey PM; Jones JL; Pinder SE; Bundred NJ; Fentiman IS; Cuzick J
    Clin Cancer Res; 2021 May; 27(10):2861-2867. PubMed ID: 33727261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contralateral breast cancer after curative-intent treatment for ductal carcinoma in situ: Rate and associated clinicopathological and imaging risk factors.
    Hovis K; Mercaldo S; Kim G; Lamb LR; Oseni TO; Bahl M
    Clin Imaging; 2022 Feb; 82():179-192. PubMed ID: 34872008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
    Liu Y; West R; Weber JD; Colditz GA
    Cancer; 2019 Sep; 125(18):3225-3233. PubMed ID: 31120565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast.
    Innos K; Horn-Ross PL
    Breast Cancer Res Treat; 2008 Oct; 111(3):531-40. PubMed ID: 17978879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with pure ductal carcinoma in situ (DCIS)?
    Benveniste AP; Ortiz-Perez T; Ebuoma LO; Sepulveda KA; Severs FJ; Roark A; Wang T; Sedgwick EL
    Eur J Radiol; 2017 Nov; 96():74-79. PubMed ID: 29103479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of a prior diagnosis of DCIS on survival from invasive breast cancer.
    Sopik V; Iqbal J; Sun P; Narod SA
    Breast Cancer Res Treat; 2016 Jul; 158(2):385-93. PubMed ID: 27383477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis.
    Rakovitch E; Nofech-Mozes S; Narod SA; Hanna W; Thiruchelvam D; Saskin R; Taylor C; Tuck A; Sengupta S; Elavathil L; Jani PA; Done SJ; Miller N; Youngson B; Kong I; Paszat L
    Breast Cancer Res Treat; 2013 Apr; 138(2):581-90. PubMed ID: 23456231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score™ result.
    Alvarado M; Carter DL; Guenther JM; Hagans J; Lei RY; Leonard CE; Manders J; Sing AP; Broder MS; Cherepanov D; Chang E; Eagan M; Hsiao W; Schultz MJ
    J Surg Oncol; 2015 Jun; 111(8):935-40. PubMed ID: 26031501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic predisposition to ductal carcinoma in situ of the breast.
    Petridis C; Brook MN; Shah V; Kohut K; Gorman P; Caneppele M; Levi D; Papouli E; Orr N; Cox A; Cross SS; Dos-Santos-Silva I; Peto J; Swerdlow A; Schoemaker MJ; Bolla MK; Wang Q; Dennis J; Michailidou K; Benitez J; González-Neira A; Tessier DC; Vincent D; Li J; Figueroa J; Kristensen V; Borresen-Dale AL; Soucy P; Simard J; Milne RL; Giles GG; Margolin S; Lindblom A; Brüning T; Brauch H; Southey MC; Hopper JL; Dörk T; Bogdanova NV; Kabisch M; Hamann U; Schmutzler RK; Meindl A; Brenner H; Arndt V; Winqvist R; Pylkäs K; Fasching PA; Beckmann MW; Lubinski J; Jakubowska A; Mulligan AM; Andrulis IL; Tollenaar RA; Devilee P; Le Marchand L; Haiman CA; Mannermaa A; Kosma VM; Radice P; Peterlongo P; Marme F; Burwinkel B; van Deurzen CH; Hollestelle A; Miller N; Kerin MJ; Lambrechts D; Floris G; Wesseling J; Flyger H; Bojesen SE; Yao S; Ambrosone CB; Chenevix-Trench G; Truong T; Guénel P; Rudolph A; Chang-Claude J; Nevanlinna H; Blomqvist C; Czene K; Brand JS; Olson JE; Couch FJ; Dunning AM; Hall P; Easton DF; Pharoah PD; Pinder SE; Schmidt MK; Tomlinson I; Roylance R; García-Closas M; Sawyer EJ
    Breast Cancer Res; 2016 Feb; 18(1):22. PubMed ID: 26884359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y.
    VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
    Am J Surg Pathol; 2016 Aug; 40(8):1090-9. PubMed ID: 27299796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
    Doebar SC; van den Broek EC; Koppert LB; Jager A; Baaijens MHA; Obdeijn IAM; van Deurzen CHM
    Breast Cancer Res Treat; 2016 Jul; 158(1):179-187. PubMed ID: 27318854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
    Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
    Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.